JP2006518343A - エネルギー減損因子を用いた良性前立腺増殖症の処置 - Google Patents

エネルギー減損因子を用いた良性前立腺増殖症の処置 Download PDF

Info

Publication number
JP2006518343A
JP2006518343A JP2006500983A JP2006500983A JP2006518343A JP 2006518343 A JP2006518343 A JP 2006518343A JP 2006500983 A JP2006500983 A JP 2006500983A JP 2006500983 A JP2006500983 A JP 2006500983A JP 2006518343 A JP2006518343 A JP 2006518343A
Authority
JP
Japan
Prior art keywords
bph
energy
factor
cells
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006500983A
Other languages
English (en)
Japanese (ja)
Inventor
ジョージ ティドマーシュ，
ハロルド イー． セリック，
ファンイン メン，
Original Assignee
スレッシュオールド ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スレッシュオールド ファーマシューティカルズ， インコーポレイテッド filed Critical スレッシュオールド ファーマシューティカルズ， インコーポレイテッド
Publication of JP2006518343A publication Critical patent/JP2006518343A/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/342—Prostate diseases, e.g. BPH, prostatitis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
JP2006500983A 2003-01-17 2004-01-16 エネルギー減損因子を用いた良性前立腺増殖症の処置 Withdrawn JP2006518343A (ja)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US44111003P 2003-01-17 2003-01-17
US44234403P 2003-01-23 2003-01-23
US45884603P 2003-03-28 2003-03-28
US45866503P 2003-03-28 2003-03-28
US45866303P 2003-03-28 2003-03-28
US46001203P 2003-04-02 2003-04-02
US47290703P 2003-05-22 2003-05-22
US48826503P 2003-07-18 2003-07-18
US49616303P 2003-08-18 2003-08-18
PCT/US2004/001146 WO2004064736A2 (en) 2003-01-17 2004-01-16 Treatment of benign prostatic hyperplasia using energolytic agents

Publications (1)

Publication Number Publication Date
JP2006518343A true JP2006518343A (ja) 2006-08-10

Family

ID=32777423

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006500983A Withdrawn JP2006518343A (ja) 2003-01-17 2004-01-16 エネルギー減損因子を用いた良性前立腺増殖症の処置
JP2006500981A Pending JP2006516571A (ja) 2003-01-17 2004-01-16 良性前立腺増殖症の処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2006500981A Pending JP2006516571A (ja) 2003-01-17 2004-01-16 良性前立腺増殖症の処置

Country Status (13)

Country Link
US (4) US6989400B2 (enExample)
EP (2) EP1592430A4 (enExample)
JP (2) JP2006518343A (enExample)
KR (2) KR20050098249A (enExample)
AU (2) AU2004206870A1 (enExample)
BR (1) BRPI0406796A (enExample)
CA (2) CA2513575A1 (enExample)
DE (1) DE04702967T1 (enExample)
ES (1) ES2254046T1 (enExample)
IL (1) IL169685A0 (enExample)
MX (2) MXPA05007572A (enExample)
NO (1) NO20053783L (enExample)
WO (2) WO2004064735A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7795227B2 (en) 2004-06-17 2010-09-14 Wisconsin Alumni Research Foundation Compounds and methods for treating seizure disorders
WO2013153821A1 (ja) * 2012-04-12 2013-10-17 Omura Satoshi Ｐｄｋ４阻害剤及びその利用

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7547673B2 (en) * 2001-09-13 2009-06-16 The Johns Hopkins University Therapeutics for cancer using 3-bromopyruvate and other selective inhibitors of ATP production
US7524885B2 (en) * 2002-04-01 2009-04-28 The Governors Of The University Of Alberta Compounds that stimulate glucose utilization and methods of use
AU2004206870A1 (en) 2003-01-17 2004-08-05 Threshold Pharmaceuticals, Inc. Treatment of benign prostatic hyperplasia using energolytic agents
US7208611B2 (en) 2005-02-23 2007-04-24 Xenoport, Inc. Platinum-containing compounds exhibiting cytostatic activity, synthesis and methods of use
US20060287253A1 (en) * 2005-06-17 2006-12-21 Kriegler Steven M Compounds and methods for treating seizure disorders
US8324175B2 (en) * 2006-02-16 2012-12-04 Young Hee Ko Compositions and methods for the treatment of cancer
KR20080096807A (ko) * 2006-02-24 2008-11-03 보오드 오브 리젠츠, 더 유니버시티 오브 텍사스 시스템 암 치료용 6탄당 화합물
KR20080114711A (ko) 2006-03-02 2008-12-31 아스텔라스세이야쿠 가부시키가이샤 17β ＨＳＤ 타입 5 저해제
WO2008076964A1 (en) * 2006-12-18 2008-06-26 The Johns Hopkins University Therapeutics for cancer using 3-bromopyruvate and other selective inhibitors of atp production
US20080245375A1 (en) * 2007-04-05 2008-10-09 Medtronic Vascular, Inc. Benign Prostatic Hyperplasia Treatments
MX2010000918A (es) 2007-07-24 2010-03-15 Astellas Pharma Inc Derivado de bencimidazol.
AU2008292420A1 (en) 2007-08-31 2009-03-05 Astellas Pharma Inc. Piperidine derivative
US8603123B2 (en) 2008-04-28 2013-12-10 Urotech, Inc. Benign prostatic hyperplasia surgical system featuring mechanical coring probe with live aspiration
WO2010021750A2 (en) 2008-08-21 2010-02-25 The Johns Hopkins University Methods and compositions for administration of 3-halopyruvate and related compounds for the treatment of cancer
WO2010088564A2 (en) * 2009-01-29 2010-08-05 Young Hee Ko Compositions and methods for the treatment of cancer
US10441561B2 (en) 2012-07-26 2019-10-15 The William M. Yanbrough Foundation Method for treating benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer
JP6552509B2 (ja) 2014-01-14 2019-07-31 ザ・ジョンズ・ホプキンス・ユニバーシティー 選択的ａｔｐ阻害剤をカプセル化するシクロデキストリン組成物およびその使用
US10751306B2 (en) 2015-11-06 2020-08-25 The Johns Hopkins University Methods of treating liver fibrosis by administering 3-bromopyruvate
EP3564214B1 (en) 2018-05-04 2024-07-03 Universita' Degli Studi G. D'annunzio Chieti - Pescara Indazole derivatives as modulators of the cannabinoid system
EP4213839A4 (en) * 2020-09-17 2024-08-07 Escient Pharmaceuticals, Inc. MODULATORS OF THE MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1052111B (it) 1972-02-29 1981-06-20 Acraf Acidi i benzil i h indazol 3 carbossilici sostituiti e loro derivati
US4684627A (en) 1981-09-08 1987-08-04 Leveen Harry H Treatment of cancer with phlorizin and its derivatives
CA1289077C (en) 1984-08-13 1991-09-17 Harry H. Leveen Treatment of cancer with phlorizin and its derivatives
US5260327A (en) * 1985-10-02 1993-11-09 Sloan-Kettering Institute For Cancer Research Methods for inhibiting the proliferation of brain and hepatic metastases by using lonidamine
WO1992018132A1 (en) * 1991-04-17 1992-10-29 Merck & Co., Inc. Pharmaceutical combination for the treatment of benign prostatic hyperplasia comtaining a 5 alpha-reductase inhibitor
US6063911A (en) * 1993-12-01 2000-05-16 Marine Polymer Technologies, Inc. Methods and compositions for treatment of cell proliferative disorders
US5654320A (en) * 1995-03-16 1997-08-05 Eli Lilly And Company Indazolecarboxamides
ATE247469T1 (de) 1995-06-07 2003-09-15 Pfizer Heterocyclische kondensierte pyrimidin-derivate
FR2737721B1 (fr) 1995-08-08 1997-09-05 Roussel Uclaf Nouveaux composes biphenyles, leur procede de preparation et les intermediaires de ce procede, leur application a titre de medicament et les compositions pharmaceutiques les contenant
EP0797564B1 (en) 1995-10-18 2001-06-27 Kanoldt Arzneimittel Gmbh Lignans, a process for their production and pharmaceutical compositions and uses thereof
DE19621319A1 (de) 1996-05-28 1997-12-04 Hoechst Ag Bis-ortho-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
US6054432A (en) 1996-09-12 2000-04-25 Asta Medica Aktiengesellschaft Means for treating prostate hypertrophy and prostate cancer
IT1289938B1 (it) 1997-02-20 1998-10-19 Angelini Ricerche Spa Preparazione farmaceutica comprendente liposomi liofilizzati in cui e' incapsulato un principio attivo altamente insolubile in acqua e
IT1289939B1 (it) 1997-02-20 1998-10-19 Angelini Ricerche Spa Composizione farmaceutica acquosa comprendente un principio attivo altamente insolubile in acqua
CN1078462C (zh) * 1997-07-09 2002-01-30 辛国芳 棉酚和/或其衍生物作为有效成分在制备用于治疗前列腺炎的栓剂中的应用
US6482802B1 (en) * 1998-05-11 2002-11-19 Endowment For Research In Human Biology, Inc. Use of neomycin for treating angiogenesis-related diseases
US6428968B1 (en) * 1999-03-15 2002-08-06 The Trustees Of The University Of Pennsylvania Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
US6001865A (en) * 1999-05-04 1999-12-14 Angelini Pharmaceuticals Inc. 3-substituted 1-benzyl-1H-indazole derivatives as antifertility agents
AU2004206870A1 (en) 2003-01-17 2004-08-05 Threshold Pharmaceuticals, Inc. Treatment of benign prostatic hyperplasia using energolytic agents
KR20080097496A (ko) * 2004-03-25 2008-11-05 더 리젠츠 오브 더 유니버시티 오브 미시간 고시폴 공결정 및 그의 용도

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7795227B2 (en) 2004-06-17 2010-09-14 Wisconsin Alumni Research Foundation Compounds and methods for treating seizure disorders
WO2013153821A1 (ja) * 2012-04-12 2013-10-17 Omura Satoshi Ｐｄｋ４阻害剤及びその利用

Also Published As

Publication number Publication date
WO2004064736A3 (en) 2005-05-06
EP1610778A2 (en) 2006-01-04
AU2004206870A1 (en) 2004-08-05
MXPA05007572A (es) 2005-11-17
AU2004206869A1 (en) 2004-08-05
NO20053783D0 (no) 2005-08-09
KR20050098250A (ko) 2005-10-11
CA2513575A1 (en) 2004-08-05
DE04702967T1 (de) 2006-06-22
WO2004064735A3 (en) 2004-12-16
ES2254046T1 (es) 2006-06-16
US20050271723A1 (en) 2005-12-08
US20050272795A1 (en) 2005-12-08
EP1610778A4 (en) 2006-05-31
NO20053783L (no) 2005-09-27
MXPA05007571A (es) 2005-11-17
KR20050098249A (ko) 2005-10-11
US6989400B2 (en) 2006-01-24
US20050272796A1 (en) 2005-12-08
CA2513572A1 (en) 2004-08-05
US20040167196A1 (en) 2004-08-26
WO2004064735A2 (en) 2004-08-05
WO2004064736A2 (en) 2004-08-05
EP1592430A2 (en) 2005-11-09
EP1592430A4 (en) 2006-05-31
IL169685A0 (en) 2007-07-04
BRPI0406796A (pt) 2006-01-17
JP2006516571A (ja) 2006-07-06

Similar Documents

Publication Publication Date Title
JP2006518343A (ja) エネルギー減損因子を用いた良性前立腺増殖症の処置
Pettus et al. Prostate size is associated with surgical difficulty but not functional outcome at 1 year after radical prostatectomy
AU742468B2 (en) Methods for treatment of conditions associated with lactosylceramide
JP2002521435A (ja) ラクトシルセラミドによって調節される病態を治療する方法
Shin et al. Clinical outcomes of non-operative treatment for patients presenting SLAP lesions in diagnostic provocative tests and MR arthrography
Ahn et al. Chronic administration of phosphodiesterase 5 inhibitor improves erectile and endothelial function in a rat model of diabetes
Mwangi et al. Glial Cell Line–Derived Neurotrophic Factor Enhances Autophagic Flux in Mouse and Rat Hepatocytes and Protects Against Palmitate Lipotoxicity
Pickard et al. Corpus cavernosal relaxation in impotent men
Prout Jr et al. Long-term experience with flutamide in patients with prostatic carcinoma
PT1033979E (pt) Combinação de inibidores da enzima cyp2a e nicotina e sua utilização terapêutica
US20060172953A1 (en) Treatment of benign prostatic hyperplasia using energolytic agents
Kim et al. The prostatic urethral angle can predict the response to alpha adrenoceptor antagonist monotherapy for treating nocturia in men with lower urinary tract symptom: A multicenter study
Boutros et al. Common cancer treatments targeting DNA double strand breaks affect long-term memory and relate to immediate early gene expression in a sex-dependent manner
ZA200505395B (en) Treatment of benign prostatic hyperplasia using energolytic agents
Schasfoort et al. Safety and efficacy of a non-steroidal anti-androgen, based on results of a post marketing surveillance of nilutamide
Weiss et al. Management of prostate diseases
Ramtohul et al. Primary Psoas Muscle Hydatid Cyst: A Case Report of a Rare Pathology.
Butler et al. Introduction to prostate brachytherapy
Kale et al. Ameliorative potential of Acridocarpus smeathmannii extracts on testosterone propionate and sleep deprivation-induced benign prostate hyperplasia rats
Altan et al. Restorative medicine in the aging genitourinary system
Martin et al. PD11-11
Brawer et al. Best of the 2007 AUA Annual Meeting: Highlights from the 2007 Annual Meeting of the American Urological Association, May 19–24, 2007, Anaheim, CA
US20030069264A1 (en) Method of determining and reducing the risk of bph-related urologic events
Konety et al. Geriatric urology
Schasfoort et al. Safety and efficacy of a non-steroidal anti-androgen, based on results of a post marketing

Legal Events

Date Code Title Description
A300 Application deemed to be withdrawn because no request for examination was validly filed

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 20070403